🔥🐔 BizChicken 🐔🔥
Companies Similar to Olema Pharmaceuticals, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
BioAtla, Inc.
BA3011
Bio Atla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Their lead product candidate is BA3011, targeting various cancers.
Symbol: BCAB
Recent Price: $0.59
Industry: Biotechnology
CEO: Dr. Jay M. Short Ph.D.
Sector: Healthcare
Employees: 65
Address: 11085 Torreyana Road, San Diego, CA 92121
Phone: 858 558 0708
Last updated: 2024-12-31
Eledon Pharmaceuticals, Inc.
AT-1501
Eledon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing medicines for autoimmune diseases, amyotrophic lateral sclerosis (ALS), and organ or cell-based transplants. Its lead product candidate AT-1501 is in Phase 2 clinical trials.
Symbol: ELDN
Recent Price: $4.14
Industry: Biotechnology
CEO: Dr. David-Alexandre C. Gros M.D., Ph.D.
Sector: Healthcare
Employees: 20
Address: 19900 MacArthur Boulevard, Irvine, CA 92612
Phone: 949 238 8090
Last updated: 2024-12-31
Ikena Oncology, Inc.
IK-930
Ikena Oncology is a targeted oncology company developing medicines tailored to biomarker-defined patient groups, with a focus on unmet needs in cancer treatment.
Symbol: IKNA
Recent Price: $1.60
Industry: Biotechnology
CEO: Dr. Mark Manfredi Ph.D.
Sector: Healthcare
Employees: 18
Address: 645 Summer Street, Boston, MA 02210
Phone: 857 273 8343
Last updated: 2024-12-31
ORIC Pharmaceuticals, Inc.
ORIC-533, ORIC-944, ORIC-114
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers and develops therapies for the treatment of cancers, focusing on overcoming resistance in chemotherapy and immunotherapy. Their product candidates target various cancer resistance mechanisms, including prostate cancer and epidermal growth factor receptor mutations.
Symbol: ORIC
Recent Price: $8.17
Industry: Biotechnology
CEO: Dr. Jacob M. Chacko M.B.A., M.D.
Sector: Healthcare
Employees: 107
Address: 240 East Grand Avenue, South San Francisco, CA 94080
Phone: 650 388 5600
Last updated: 2024-12-31
Omeros Corporation
Narsoplimab
Omeros Corporation is a commercial-stage biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for inflammation, immune-related cancers, and addictive disorders.
Symbol: OMER
Recent Price: $9.74
Industry: Biotechnology
CEO: Dr. Gregory A. Demopulos M.D.
Sector: Healthcare
Employees: 198
Address: The Omeros Building, Seattle, WA 98119
Phone: 206 676 5000
Last updated: 2024-12-31
Oncternal Therapeutics, Inc.
zilovertamab, ONCT-216, ONCT-808, ONCT-534
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.
Symbol: ONCT
Recent Price: $0.53
Industry: Biotechnology
CEO: Dr. James B. Breitmeyer M.D., Ph.D.
Sector: Healthcare
Employees: 27
Address: 12230 El Camino Real, San Diego, CA 92130
Phone: 858 434 1113
Last updated: 2024-12-31
ALX Oncology Holdings Inc.
ALX148
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company developing therapies for cancer patients. Its lead product, ALX148, targets CD47 and is in trials for various cancers. The company also explores pre-clinical treatments like ALTA-002 to enhance immune response to cancer.
About | Contact | About | About | Careers | Careers | Jobs | Jobs | Jobs | Jobs | Careers | About | About | Careers | Jobs
Symbol: ALXO
Recent Price: $1.66
Industry: Biotechnology
CEO: Mr. Jason W. Lettmann
Sector: Healthcare
Employees: 81
Address: 323 Allerton Avenue, South San Francisco, CA 94080
Phone: 650 466 7125
Last updated: 2024-12-31
Apollomics, Inc.
APL-101 (Vebreltinib), APL-102, APL-122
Apollomics, Inc. is a biotechnology company that discovers and develops oncology therapies to address unmet medical needs, focusing on treatments for non-small cell lung cancer, liver cancer, breast cancer, esophageal cancer, and brain tumors.
Symbol: APLM
Recent Price: $10.13
Industry: Biotechnology
CEO: Dr. Guo-Liang Yu Ph.D.
Sector: Healthcare
Employees: 45
Address: 989 East Hillsdale Blvd, Foster City, CA 94404
Phone: 650 209 4055
Last updated: 2024-12-31
Atossa Therapeutics, Inc.
Endoxifen
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for oncology and infectious diseases with key programs in breast cancer and COVID-19 treatment.
Symbol: ATOS
Recent Price: $0.97
Industry: Biotechnology
CEO: Dr. Steven C. Quay FCAP, M.D., Ph.D.
Sector: Healthcare
Employees: 12
Address: 107 Spring Street, Seattle, WA 98104
Phone: 206 588 0256
Last updated: 2024-12-31
BioCryst Pharmaceuticals, Inc.
ORLADEYO
Bio Cryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering novel, oral, and small-molecule medicines, with marketed products including RAPIVAB and ORLADEYO, and a pipeline featuring BCX9930, BCX9250, and Galidesivir.
About | About | About | Contact | Careers | Careers | Safety | Jobs | Careers | About | About | About | About
Symbol: BCRX
Recent Price: $7.53
Industry: Biotechnology
CEO: Mr. Jon P. Stonehouse
Sector: Healthcare
Employees: 536
Address: 4505 Emperor Boulevard, Durham, NC 27703
Phone: 919 859 1302
Last updated: 2024-12-31
89bio, Inc.
pegozafermin
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardio-metabolic diseases, primarily through its lead product candidate, pegozafermin, designed to treat nonalcoholic steatohepatitis and severe hypertriglyceridemia.
Symbol: ETNB
Recent Price: $7.87
Industry: Biotechnology
CEO: Mr. Rohan Palekar
Sector: Healthcare
Employees: 70
Address: 142 Sansome Street, San Francisco, CA 94104
Phone: 415 432 9270
Last updated: 2024-12-31
Compass Therapeutics, Inc.
CTX-009, CTX-471, CTX-8371
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.
Symbol: CMPX
Recent Price: $1.48
Industry: Biotechnology
CEO: Dr. Thomas J. Schuetz M.D., Ph.D.
Sector: Healthcare
Employees: 32
Address: 80 Guest Street, Boston, MA 02135
Phone: 617 500 8099
Last updated: 2024-12-31
Olema Pharmaceuticals, Inc.
OP-1250
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, in clinical trials for breast cancer.
Symbol: OLMA
Recent Price: $5.61
Industry: Biotechnology
CEO: Dr. Sean P. Bohen M.D., Ph.D.
Sector: Healthcare
Employees: 80
Address: 512 2nd Street, San Francisco, CA 94107
Phone: 650 243 5555
Last updated: 2024-12-31
Omega Therapeutics, Inc.
OMEGA Epigenomic Programming platform
Omega Therapeutics, Inc. is a development-stage biopharmaceutical company leveraging its OMEGA Epigenomic Programming platform to utilize the power of epigenetics for therapeutic interventions across various diseases.
About | Vision/Values | Leadership | Leadership | About | Contact | Contact | About | About
Symbol: OMGA
Recent Price: $0.80
Industry: Biotechnology
CEO: Mr. Mahesh Karande
Sector: Healthcare
Employees: 93
Address: 20 Acorn Park Drive, Cambridge, MA 02140
Phone: 617 949 4360
Leadership
- Mahesh Karande, President & Chief Executive Officer
- Kaan Certel, Ph.D., Chief Business Officer
- Jennifer Nelson, Ph.D., Senior Vice President, Research
- Tony Mullin, Chief People Officer
- Barbara Chan, Senior Vice President, Finance and Chief Accounting Officer
- Lisamarie Fahy, Senior Vice President, Clinical Development Operations
- Joe Newman, Ph.D., Senior Vice President, Early Discovery
- Jeff Atkinson, Ph.D., Vice President, Technical Operations
- Eva Stroynowski, Senior Vice President, Investor Relations and Corporate Affairs
Last updated: 2024-12-31
Ovid Therapeutics Inc.
OV101, OV329, OV350, OV882, OV815
Ovid Therapeutics Inc., a biopharmaceutical company based in New York, is dedicated to developing impactful medicines for neurological disorders. They have a range of drug candidates like OV101 and are involved in various clinical trials.
Our Story | Leadership | Directors | About | Our Story | Contact | About | About | About | About | About | Culture | Culture | Vision/Values | Culture | About | Culture | Culture | About | Jobs | Careers | Careers | Jobs | About | About | About | Careers | Vision/Values | About | About | About | About | About | About
Symbol: OVID
Recent Price: $0.96
Industry: Biotechnology
CEO: Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Sector: Healthcare
Employees: 40
Address: 1460 Broadway, New York, NY 10036
Phone: 646 661 7661
Leadership
- Jeremy M. Levin, D.Phil, MB BChir, Chief Executive Officer and Chairman
- Meg Alexander, President and Chief Operating Officer
- Zhong Zhong, Ph.D., Chief Scientific Officer
- Jeffrey Rona, Chief Business and Financial Officer
- Amanda Banks, M.D., Chief Development Officer
- Julia Tsai, Ph.D., Senior Vice President of Clinical Development
- Karen Bernstein, Ph.D., Director, Chair of the Compensation Committee, Member of the Audit and Nominating and Corporate Governance Committees
- Barbara G. Duncan, MBA, Director, Chair of the Audit Committee, Member of the Nominating and Corporate Governance Committee
- Bart Friedman, J.D., Lead Independent Director, Chair of the Nominating and Corporate Governance Committee, Member of the Audit and Compensation Committees
- Michael Poole, M.D., FACP, Director, Member of the Audit and Compensation Committees
- Kevin Fitzgerald, Ph.D., Director, Member of the Nominating and Corporate Governance Committee
Last updated: 2024-12-31
Poseida Therapeutics, Inc.
P-PSMA-101
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on developing innovative CAR-T therapies for patients with high unmet medical needs, including treatments for prostate cancer, multiple myeloma, and various solid tumors.
Symbol: PSTX
Recent Price: $9.48
Industry: Biotechnology
CEO: Dr. Kristin Yarema Ph.D.
Sector: Healthcare
Employees: 337
Address: 9390 Towne Centre Drive, San Diego, CA 92121
Phone: 858 779 3100
Last updated: 2024-12-31
XOMA Corporation
Pre-commercial therapeutic candidates
XOMA Corporation operates as a biotechnology royalty aggregator focusing on enhancing human health by acquiring potential future economics from pre-commercial therapeutic candidates licensed to pharmaceutical or biotech companies. With a portfolio of approximately 70 assets, it focuses on early to mid-stage clinical assets with commercial sales potential.
Symbol: XOMA
Recent Price: $26.09
Industry: Biotechnology
CEO: Mr. Owen P. Hughes Jr.
Sector: Healthcare
Employees: 13
Address: 2200 Powell Street, EmeryVille, CA 94608
Phone: 510 204 7200
Last updated: 2024-12-31
Immix Biopharma, Inc.
IMX-110, IMX-111, IMX-120
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation, with clinical trials across the United States and Australia.
Symbol: IMMX
Recent Price: $2.36
Industry: Biotechnology
CEO: Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Sector: Healthcare
Employees: 14
Address: 11400 West Olympic Boulevard, Los Angeles, CA 90064
Phone: 310 651 8041
Last updated: 2024-12-31
Panbela Therapeutics, Inc.
SBP-101
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for treating various cancers, including pancreatic and ovarian cancers. Its lead product, SBP-101, is undergoing clinical trials for pancreatic cancer treatment.
Symbol: PBLA
Recent Price: $0.32
Industry: Biotechnology
CEO: Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.
Sector: Healthcare
Employees: 7
Address: 712 Vista Boulevard, Waconia, MN 55387
Phone: 952 479 1196
Leadership
- Michael T. Cullen, MD, MBA, Chairman, President and Chief Executive Officer
- Jennifer K Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer
- Art Fratamico, MBA, Chief Business Officer
- Dan Donovan, CEO of rareLife Solutions, Inc.
- Jeff Mathiesen, Director and Audit Committee Chair
- Jeffrey Jacob, CEO at Cancer Prevention Pharmaceuticals, Inc.
- Robert Schemel, Director
- David Harle, Ph.D., Executive with over 25 years of pharmaceutical experience
- Mr. Donovan, CEO of rareLife Solutions, Inc.
Last updated: 2024-12-31
Seelos Therapeutics, Inc.
SLS-002, SLS-005, SLS-006, SLS-007, SLS-008, SLS-004, SLS-010
Seelos Therapeutics, Inc. is focused on developing and commercializing therapeutics for central nervous system, respiratory, and other disorders, with lead programs targeting major depressive disorders, amyotrophic lateral sclerosis, Sanfilippo syndrome, and Parkinson's disease.
Symbol: SEEL
Recent Price: $0.37
Industry: Biotechnology
CEO: Dr. Raj Mehra J.D., Ph.D.
Sector: Healthcare
Employees: 8
Address: 300 Park Avenue, New York, NY 10022
Phone: 646 293 2100
Last updated: 2024-12-31